Surrozen, Inc./DE (SRZNW) Financial Analysis and Rating

Comparison Analysis Based on SEC Data

Company Name Surrozen, Inc./DE
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances
Revenue in 2025 $3,477 thousand (ranked #375 out of 508 companies in the industry)
Assets as of 12/31/2025 $98,726 thousand (ranked #355)
Analyzed report 12/31/2024 (filed 3/31/2025)

Year:
20242025

Financial Position and Performance
Annual | Quarterly

Compared with 2024 industry ratios Change during the year

worse
deteriorated significantly
Compared with all listed companies

worse

Compare with a competitor

Financial Ratios Benchmarking

Financial Ratio Comparison of company ratios for 2024
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Solvency Ratios
Debt ratio 
1.44
0.48
1.44
0.61
Liquidity Ratios
Current Ratio 
5.32
3.20
5.32
1.78
Quick Ratio 
5.00
1.84
5.00
1.06
Cash Ratio 
4.73
1.81
4.73
0.59
Profitability Ratios
Profit margin 
-596.6%
-108.7%
-596.6%
3%
ROE (Return on equity), after tax 
-765.8%
-36.2%
-765.8%
5.1%
ROA (Return on assets) 
-134.1%
-25.1%
-134.1%
0.9%
Activity Ratios
Asset turnover (days) 
1624
1274
1624
776
Receivables turnover (days) 
72
60
72
48
Resulting score -0,6 -0,6

Year:
20242025

Additional Ratios (not used in score calculation)

Financial Ratio Comparison of company ratios for 2024
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Price Ratios
Earnings per Share (basic)  $-21.67
Earnings per Share (diluted)  $-21.67

Auditor's Conclusion

We have performed a comparative analysis of the balance sheet and income statement of Surrozen, Inc./DE (hereafter – the "Company") for the year 2024 as filed with the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Biological Products, Except Diagnostic Substances" (SIC code 2836). In our analysis, we compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the Company's specific industry sector and for all companies. The averages were calculated using data from 2024 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have reached an overall conclusion about the quality of the Company's financial condition. All calculations and conclusions were performed using software and methodologies developed by ReadyRatios.

Based on our analysis of the Company's key financial ratios, we have determined the following. The financial condition of Surrozen, Inc./DE in 2024 is worse than the typical financial condition of companies in the "Biological Products, Except Diagnostic Substances" industry.

This conclusion is supported by a comparison of the Company's financial ratios with average U.S. ratios. The financial position of Surrozen, Inc./DE is worse than that of most listed companies that file financial statements with the U.S. Securities and Exchange Commission.

Financial Position and Performance History


More on Surrozen, Inc./DE

Closest Competitors

Company USD ($), in Millions
Revenue Assets
CG Oncology, Inc. 4 792
CRISPR Therapeutics AG 4 2,265
Revolution